Gene Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03843775	Phase Ib/II	Binimetinib + Encorafenib	A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers	Completed	USA	0
NCT04913285	Phase I	Binimetinib + Exarafenib Exarafenib	A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors	Recruiting	USA \| NLD \| FRA \| ESP \| AUS	3
NCT05512208	Phase II	Defactinib + RO5126766	A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK)	Recruiting	USA	0
NCT05355701	Phase I	Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	Recruiting	USA \| CAN	1
NCT04418661	Phase Ib/II	Pembrolizumab + RMC-4630 Adagrasib + RMC-4630	Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies	Active, not recruiting	USA \| NLD \| ESP \| AUS	4
NCT06270082	Phase I	IK-595	Study of IK-595 in RAS- or RAF-altered Advanced Tumors	Recruiting	USA	0
NCT05580770	Phase Ib/II	BGB3245 + PD-0325901	Mirdametinib + BGB-3245 in Advanced Solid Tumors	Recruiting	USA \| AUS	0
NCT05786924	Phase I	BDTX-4933	A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers	Recruiting	USA	0
NCT04589845	Phase II	Alectinib Ado-trastuzumab emtansine Ipatasertib Inavolisib Entrectinib Atezolizumab Idasanutlin	Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Recruiting	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	14
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT04201457	Phase Ib/II	Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	Recruiting	USA	0
NCT02925234	Phase II	Palbociclib Ribociclib Lenvatinib Ipilimumab + Nivolumab Trametinib Crizotinib Niraparib Selpercatinib Olaparib Erlotinib Erdafitinib Dabrafenib Dacomitinib Rucaparib Axitinib Panitumumab Pemigatinib Durvalumab Afatinib Entrectinib Tepotinib Alpelisib Atezolizumab + Bevacizumab Alectinib Regorafenib Cobimetinib + Vemurafenib Nilotinib Vismodegib Abemaciclib Sunitinib Nivolumab Cabozantinib Lorlatinib Talazoparib Dabrafenib + Trametinib Pembrolizumab Pertuzumab + Trastuzumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT04923126	Phase Ib/II	PD-0325901	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT03839342	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)	Active, not recruiting	CAN	0
NCT02296112	Phase II	Trametinib	Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations	Completed	USA	0
NCT05554367	Phase II	Binimetinib + Palbociclib	Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	0
NCT04985604	Phase Ib/II	Pimasertib + Tovorafenib Tovorafenib	Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors	Recruiting	USA \| FRA \| ESP \| CAN \| BEL \| AUS	1
NCT04534283	Phase II	Abemaciclib + LY3214996	A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.	Terminated	USA	0
NCT04390243	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation	Terminated	USA	0
NCT04249843	Phase I	BGB3245	Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors	Recruiting	USA \| AUS	0
NCT05111561	Phase I	Binimetinib + ZEN-3694	Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer	Recruiting	USA	0
NCT05503797	Phase II	Cobicistat + PLX8394 PLX8394	A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN	2
NCT02587650	Phase II	Ceritinib Capmatinib Regorafenib Entrectinib	Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma	Terminated	USA	0
NCT02285439	Phase Ib/II	Binimetinib	Study of MEK162 for Children With Low-Grade Gliomas	Active, not recruiting	USA	0
NCT04775485	Phase II	Tovorafenib	A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors (FIREFLY-1)	Recruiting	USA \| NLD \| GBR \| DEU \| CAN \| AUS	5
NCT04418167	Phase I	JSI-1187 Dabrafenib + JSI-1187	JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations	Suspended	USA	0
NCT06104488	Phase I	RO5126766	A Study of Avutometinib for People With Solid Tumor Cancers	Recruiting	USA	0
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Active, not recruiting	USA \| NLD \| ITA \| ESP	1
NCT04759846	Phase I	Binimetinib + Encorafenib	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	Withdrawn	ITA \| ESP	1
NCT02465060	Phase II	Nivolumab + Relatlimab Dabrafenib + Trametinib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT04657991	Phase III	Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	Active, not recruiting	USA \| NZL \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	17
NCT03973918	Phase II	Binimetinib + Encorafenib	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)	Terminated	USA	0
NCT03898908	Phase II	Binimetinib + Encorafenib	Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)	Active, not recruiting	ESP	0
NCT05270044	Phase III	Binimetinib + Encorafenib	Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)	Active, not recruiting	NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	13
NCT05926960	Phase II	Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab	A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)	Recruiting	ITA \| GBR \| ESP \| DEU	3
NCT05097378	Phase II	Binimetinib + Encorafenib	Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)	Unknown status	GBR	0
NCT03878719	Phase I	Binimetinib + Encorafenib	Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Terminated	ITA	0
NCT03235245	Phase II	Binimetinib + Encorafenib Ipilimumab + Nivolumab	Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)	Active, not recruiting	NLD \| ITA \| GBR \| FRA \| ESP \| DEU	3
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT02130466	Phase Ib/II	Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	Completed		0
NCT04074096	Phase II	Binimetinib + Encorafenib + Pembrolizumab	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)	Recruiting	FRA	0
NCT05203172	FDA approved	Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	8
NCT03864042	Phase I	Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib	Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors	Active, not recruiting	USA \| NLD \| ESP \| CAN \| BEL	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT01659151	Phase II	Aldesleukin Fludarabine Vemurafenib	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma	Active, not recruiting	USA	0
NCT04557956	Phase Ib/II	Tazemetostat Dabrafenib + Tazemetostat + Trametinib	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	Recruiting	USA	0
NCT03975231	Phase I	Dabrafenib + Trametinib	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT02257424	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)	Completed	USA	0
NCT06194929	Phase Ib/II	Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766	Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)	Recruiting	USA	0
NCT04310397	Phase II	Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	Completed	USA	0
NCT06284460	Phase Ib/II	ASTX029 ASTX029 + Decitabine and Cedazuridine	Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms	Not yet recruiting	USA	0
NCT01765543	Phase I	Rifampin + Vemurafenib	A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy	Completed	USA	4
NCT01586195	Phase II	Vemurafenib	Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E	Terminated	USA	0
NCT04683250	Phase Ib/II	Vepafestinib	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))	Recruiting	USA	1
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT02949843	Phase II	Nivolumab + Pembrolizumab	Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations	Terminated	USA	0
NCT02140840	Phase II	Trametinib	A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib	Withdrawn	USA	0
NCT04984811	Phase II	Atezolizumab + NT-I7	NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC	Active, not recruiting	USA	0
NCT04699188	Phase Ib/II	JDQ443 JDQ443 + TNO155 JDQ443 + Tislelizumab + TNO155 JDQ443 + Tislelizumab	Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-01)	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	7
NCT03516981	Phase II	MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab	A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)	Active, not recruiting	USA \| ITA \| GBR \| ESP \| CAN \| AUS	10
NCT05935774	Phase II	Atezolizumab + Trabedersen	OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer	Withdrawn	USA	0
NCT04169841	Phase II	Durvalumab + Olaparib + Tremelimumab	Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR)	Active, not recruiting	FRA	0
NCT04644237	Phase II	Trastuzumab deruxtecan	Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| AUS	3
NCT01713972	Phase I	Dabrafenib + Pazopanib	Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors	Completed	USA	0
NCT04265534	Phase II	Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium	KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE)	Terminated	USA	0
NCT05566795	Phase III	Tovorafenib	DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)	Recruiting	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	13
NCT05671510	Phase III	ONC-392 Docetaxel	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT05513703	Phase II	Telisotuzumab vedotin	A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ITA \| FRA \| DEU \| AUS	4
NCT05555732	Phase III	Datopotamab deruxtecan + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Datopotamab deruxtecan + Pembrolizumab Cisplatin + Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	13
NCT05554380	Phase II	Ipatasertib + Paclitaxel	Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT05340621	Phase Ib/II	Binimetinib + OKI-179	NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)	Active, not recruiting	USA	0
NCT05313009	Phase Ib/II	Sotorasib + TH-4000	Tarlox and Sotorasib in Patients With KRAS G12C Mutations	Terminated	USA	0
NCT06208124	Phase Ib/II	IMM-6-415	A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors	Recruiting	USA	0
NCT05554328	Phase II	Selumetinib Olaparib + Selumetinib	Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial	Recruiting	USA	1
NCT05597800	Phase II	Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel	Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR)	Not yet recruiting	ITA	0
NCT03429803	Phase I	Tovorafenib	DAY101 In Gliomas and Other Tumors	Active, not recruiting	USA	0
NCT03665129	Phase I	Avdoralimab + Durvalumab	IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001)	Terminated	USA \| FRA	0
NCT03088176	Phase I	Dabrafenib + Talimogene laherparepvec + Trametinib	Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma	Unknown status	USA	0
NCT05687266	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Durvalumab Cisplatin + Pembrolizumab + Pemetrexed Disodium	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUT	16
NCT04484142	Phase II	Datopotamab deruxtecan	Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU	4
NCT05006794	Phase I	GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716	Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies	Recruiting	USA	1
NCT06194877	Phase I	BGB3245 + Panitumumab	A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers	Recruiting	USA	0
NCT03114319	Phase I	TNO155	Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors	Recruiting	USA \| NLD \| ITA \| ESP \| CAN	4
NCT01636622	Phase I	Carboplatin + Paclitaxel + Vemurafenib	Study of Vemurafenib, Carboplatin, and Paclitaxel	Completed	USA	0
NCT04467801	Phase II	Ipatasertib Docetaxel + Ipatasertib	Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)	Recruiting	USA	0
NCT04108026	Phase II	Durvalumab	Immunotherapy in Patient With Poor General Condition (SAVIMMUNE)	Active, not recruiting	FRA	0
NCT03310541	Phase I	Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant	AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations	Completed	USA	0
NCT04811001	Phase II	Dacomitinib Osimertinib	Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND)	Recruiting	ITA	0
NCT04222972	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	14
NCT02012231	Phase Ib/II	PLX8394	Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.	Terminated	USA	0
NCT01596140	Phase I	Temsirolimus + Vemurafenib Everolimus + Vemurafenib	Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer	Completed	USA	0
NCT02367859	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	Completed	USA	0
NCT04487106	Phase II	Azacitidine + Trametinib + Venetoclax	Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome	Completed	USA	0
NCT04166487	Phase II	Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium	Plasma-Adapted First-Line Pembro In NSCLC	Active, not recruiting	USA	0
NCT04526691	Phase I	Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)	Active, not recruiting	USA \| ITA \| ESP	2
NCT05541822	Phase II	ABN401	To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation	Recruiting	USA	2
NCT05200481	Phase II	Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Recruiting	FRA	0
NCT01657591	Phase I	Vemurafenib + XL888	Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma	Completed	USA	0
NCT01682213	Phase II	Dabrafenib	Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation	Completed	USA	0
NCT03455764	Phase Ib/II	Dabrafenib + MCS110 + Trametinib	MCS110 With BRAF/MEK Inhibition in Patients With Melanoma	Active, not recruiting	USA	0
NCT03272464	Phase I	Dabrafenib + Itacitinib + Trametinib	INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.	Terminated	USA	0
NCT02224781	Phase III	Ipilimumab + Nivolumab Dabrafenib + Trametinib	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Active, not recruiting	USA	0
NCT02027961	Phase Ib/II	Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib	Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone	Completed	USA \| ITA \| FRA \| CAN	0
NCT01947023	Phase I	Dabrafenib + Lapatinib	Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT04527549	Phase II	Dabrafenib + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib	Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	Active, not recruiting	USA	0
NCT03101254	Phase Ib/II	Cobimetinib + LY3022855 + Vemurafenib	LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma	Active, not recruiting	USA	0
NCT03551626	Phase III	Dabrafenib + Trametinib	Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus)	Completed	ITA \| GBR \| FRA \| CAN \| AUS	18
NCT01909453	Phase III	Vemurafenib Encorafenib Binimetinib + Encorafenib	Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	20
NCT01781026	Phase II	Vemurafenib	Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases	Completed	USA	0
NCT01682083	Phase III	Dabrafenib + Trametinib	Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)	Completed	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	13
NCT01495988	Phase II	Bevacizumab Vemurafenib	Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma	Terminated	USA	0
NCT02200562	Phase Ib/II	Dabrafenib + Ipilimumab	Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma	Terminated	USA	0
NCT02818023	Phase I	Cobimetinib + Pembrolizumab + Vemurafenib	Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma	Terminated	USA	0
NCT02196181	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT01978236	Phase II	Dabrafenib + Trametinib Dabrafenib	Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites	Terminated	USA \| AUS	0
NCT02097225	Phase I	Dabrafenib + Onalespib + Trametinib	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Unknown status	USA	0
NCT01989585	Phase Ib/II	Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	Active, not recruiting	USA	0
NCT01767454	Phase I	Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab	Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma	Completed	USA	0
NCT01585415	Phase I	Vandetanib	Vemurafenib and White Blood Cell Therapy for Advanced Melanoma	Terminated	USA	0
NCT06079333	Phase II	Dabrafenib + Trametinib	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)	Recruiting	NLD	0
NCT04655157	Phase Ib/II	Encorafenib + Ipilimumab + Nivolumab Binimetinib + Encorafenib + Ipilimumab + Nivolumab	Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)	Active, not recruiting	USA	0
NCT01940809	Phase II	Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery	Terminated	USA	0
NCT02427893	Phase III	Cobimetinib Vemurafenib	Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma	Withdrawn	USA	0
NCT01512251	Phase Ib/II	Buparlisib + Vemurafenib	BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma	Completed	USA	0
NCT03026517	Phase I	Dabrafenib + Phenformin + Trametinib	Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma	Active, not recruiting	USA	0
NCT02124772	Phase I	Trametinib Dabrafenib + Trametinib	Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations	Completed	USA \| GBR \| FRA \| CAN \| AUS	0
NCT04544111	Phase II	Dabrafenib + Spartalizumab Spartalizumab + Trametinib	PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer	Active, not recruiting	USA	0
NCT03714958	Phase I	Siremadlin + Trametinib	Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)	Completed	FRA	0
NCT03175224	Phase Ib/II	Vebreltinib	APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)	Recruiting	USA \| ITA \| GBR \| FRA \| ESP \| CAN \| AUS	6
NCT01877811	Phase Ib/II	RXDX-105	CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2	Completed	USA	0
NCT04916236	Phase I	LY3214996 + RMC-4630	Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA)	Recruiting	NLD	0
NCT05538130	Phase I	PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933	A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors	Recruiting	USA \| CAN	0
NCT04061980	Phase II	Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab	Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer	Recruiting	USA	0
NCT03244956	Phase II	Trametinib Dabrafenib + Trametinib	Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE)	Unknown status	FRA	0
NCT01721603	Phase II	Dabrafenib	A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases	Terminated	USA	0
NCT03639714	Phase Ib/II	GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab	A Study of a Personalized Neoantigen Cancer Vaccine	Completed	USA \| AUS	0
NCT04581824	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU	7
NCT03803553	Phase III	Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin	Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer	Recruiting	USA	0
NCT03365882	Phase II	Cetuximab + Irinotecan Pertuzumab + Trastuzumab	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	Active, not recruiting	USA	1
NCT05364645	Phase II	Carboplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium + Selpercatinib	Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT02164916	Phase II	Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib	S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer	Completed	USA	0
NCT05954871	Phase I	Cetuximab + GDC-1971 GDC-1971 + Osimertinib	Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer	Recruiting	USA \| AUS	1
NCT05743036	Phase Ib/II	Cetuximab + Encorafenib + ZN-c3	ZN-c3 in Adult Participants With Metastatic Colorectal Cancer	Recruiting	USA \| ITA \| ESP \| DEU \| AUS	2
NCT04252339	Phase I	GDC-1971	RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors	Completed	USA	0
NCT03224767	Phase II	Cobimetinib + Vemurafenib	Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma	Recruiting	USA	0
NCT04117945	Phase II	Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab	Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT05564403	Phase II	Fluorouracil + Leucovorin + Oxaliplatin Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin	Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)	Recruiting	USA	0
NCT05510895	Phase II	Binimetinib + Cetuximab + Encorafenib	Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)	Recruiting	DEU	0
NCT04526782	Phase II	Docetaxel Binimetinib + Encorafenib	ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)	Recruiting	FRA	0
NCT05854498	Phase II	Bevacizumab + Liposomal irinotecan + Trifluridine-tipiracil hydrochloride	Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer	Recruiting	USA	0
NCT02915666	Phase I	Dabrafenib + Digoxin + Trametinib	A Clinical Trial of Patients With Melanoma	Withdrawn	USA	0
NCT04675710	Phase II	Dabrafenib + Pembrolizumab + Trametinib	Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT04166409	Phase III	Selumetinib Carboplatin + Vincristine Sulfate	A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma	Recruiting	USA \| CAN	1
NCT04151563	Phase Ib/II	Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab	A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy	Withdrawn	USA \| NLD \| BEL	7
NCT06119581	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Cisplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium LY3537982 + Pembrolizumab Carboplatin + LY3537982 + Pembrolizumab + Pemetrexed Disodium	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	18
NCT04746924	Phase III	Tislelizumab BGBA1217 + Tislelizumab Pembrolizumab	A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer	Recruiting	USA \| FRA \| DEU	6
NCT05985954	Phase I	Cetuximab + Encorafenib + Ulixertinib Cetuximab + Ulixertinib	Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy	Recruiting	USA	0
NCT05480306	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin	Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe)	Recruiting	USA \| DEU	1
NCT04793815	FDA approved	Pembrolizumab	Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)	Completed	CAN	0
NCT01089101	Phase Ib/II	Selumetinib	Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma	Active, not recruiting	USA	0
NCT04862780	Phase Ib/II	BLU-945 BLU-945 + Osimertinib	(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	Active, not recruiting	USA \| NLD \| GBR \| FRA \| ESP \| CAN	4
NCT05048797	Phase III	Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan	A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations	Recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	11
NCT01748149	Phase I	Vemurafenib	Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas	Active, not recruiting	USA \| CAN	0
NCT05650879	Phase I	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)	Recruiting	USA \| ITA \| FRA \| ESP \| AUS	2
NCT03138889	Phase Ib/II	NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium	Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors	Terminated	USA \| FRA \| ESP \| DEU \| AUS	0
NCT05330429	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin	Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT05565417	Phase Ib/II	IMT-009	Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	USA	0
NCT04995523	Phase Ib/II	AZD2936	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)	Active, not recruiting	USA \| NLD \| FRA \| ESP \| BEL \| AUS	8
NCT01754376	Phase II	Aldesleukin + Vemurafenib	Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma	Terminated	USA	0
NCT04585815	Phase Ib/II	Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591	Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)	Active, not recruiting	USA \| GBR \| BEL \| AUS	1
NCT01336634	Phase II	Dabrafenib Dabrafenib + Trametinib	Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	4
NCT04268550	Phase II	Selpercatinib	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)	Active, not recruiting	USA	0
NCT05039177	Phase Ib/II	Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib	A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)	Active, not recruiting	USA	0
NCT05676749	Phase I	Aldesleukin + C-TIL051 + Pembrolizumab	C-TIL051 in Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT04736173	Phase III	Zimberelimab Carboplatin + Paclitaxel + Pemetrexed Disodium AB154 + Zimberelimab Pembrolizumab	Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)	Active, not recruiting	USA \| FRA	16
NCT05589818	Phase II	Pembrolizumab	Pembrolizumab for Advanced NSCLC and PS 2-3	Recruiting	USA	0
NCT01709292	Phase II	Vemurafenib	Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer	Active, not recruiting	USA	0
NCT05064280	Phase II	Lenvatinib Pembrolizumab	Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases	Recruiting	USA	0
NCT02065063	Phase I	Palbociclib + Trametinib	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors	Completed	USA	0
NCT05005273	Phase II	Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab	A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer	Completed	USA \| ITA \| FRA \| ESP \| DEU \| BEL \| AUS	5
NCT06369259	Phase II	Cetuximab + Defactinib + RO5126766	Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer	Not yet recruiting	USA	0
NCT03840915	Phase Ib/II	Bintrafusp alfa + Cisplatin + Pemetrexed Disodium Bintrafusp alfa + Docetaxel Bintrafusp alfa + Carboplatin + Pemetrexed Disodium Bintrafusp alfa + Cisplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Gemcitabine Bintrafusp alfa + Carboplatin + Nab-paclitaxel	M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)	Completed	USA \| FRA \| BEL	0
NCT06102902	Phase I	Cetuximab + Encorafenib + ZEN-3694	Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer	Recruiting	USA	0
NCT04623775	Phase II	Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab	A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT \| AUS	9
NCT06107413	Phase II	ABBV-400 + Bevacizumab + Fluorouracil + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Recruiting	USA	4
NCT05182931	Phase II	Dabrafenib + Trametinib Trametinib	A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST)	Recruiting	AUS	0
NCT06074588	Phase III	Docetaxel SKB264 Pemetrexed Disodium	MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Recruiting	USA \| CAN \| AUS	6
NCT01711632	Phase II	Vemurafenib	BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia	Active, not recruiting	USA	0
NCT03608046	Phase II	Avelumab + Cetuximab + Irinotecan	Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI)	Unknown status	BEL	0
NCT05308446	Phase II	Cetuximab + Encorafenib Cetuximab + Encorafenib + Nivolumab	Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	Recruiting	USA	1
NCT03520686	Phase III	Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab	QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.	Active, not recruiting	USA	0
NCT02675946	Phase I	CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib	CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)	Unknown status	USA	1
NCT01726738	Phase II	Dabrafenib + Trametinib	LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations	Completed	USA	0
NCT03255083	Phase I	DS-1205c + Osimertinib	DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Terminated		1
NCT05706779	Phase II	Cetuximab + Encorafenib	Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)	Recruiting	FRA	0
NCT05462613	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin	Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02)	Recruiting	FRA	0
NCT04140500	Phase I	RO7247669	Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors	Recruiting	USA \| GBR \| ESP	10
NCT05469178	Phase Ib/II	Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium	A Study to Investigate the Safety, Tolerability, and Preliminary Anti-tumor Activity of Bemcentinib in Combination With Pembrolizumab Plus Pemetrexed and Carboplatin in Adult Participants With Untreated Non-squamous Non-small Cell Lung Cancer	Recruiting	USA	0
NCT01534897	Phase I	Dabrafenib	Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436	Completed	USA	0
NCT01740648	Phase I	Fluorouracil + Trametinib	Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer	Completed	USA	0
NCT02928224	Phase III	Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	16
NCT02014909	Phase I	CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib	A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors	Completed	USA	0
NCT02178722	Phase Ib/II	Epacadostat + Pembrolizumab	Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers	Completed	USA	0
NCT05217446	Phase II	Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab	A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	6
NCT06094296	Phase II	Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel	A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)	Recruiting	USA \| ITA \| FRA \| ESP	4
NCT05453799	Phase II	XmAb20717	Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer	Recruiting	USA	0
NCT03732703	Phase Ib/II	Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide	Myeloma-Developing Regimens Using Genomics (MyDRUG) (MyDRUG)	Unknown status	USA	0
NCT04034459	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin	FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116)	Active, not recruiting	DEU	0
NCT04238624	Phase II	Cemiplimab + Dabrafenib + Trametinib	Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT05694936	Phase II	Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid	Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer	Recruiting	AUS	0
NCT01943422	Phase Ib/II	Interferon alpha-2b + Vemurafenib	Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma	Completed	USA	0
NCT05788926	Phase I	TG6050	A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)	Recruiting	FRA	0
NCT05141721	Phase II	Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab	A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT01876641	Phase Ib/II	Decitabine + Vemurafenib	Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib	Terminated	USA	0
NCT04607421	Phase III	Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer	Recruiting	USA \| NZL \| NLD \| ITA \| GBR \| ESP \| DEU \| CAN \| BEL \| AUS	19
NCT04126733	Phase II	Nivolumab + Regorafenib	Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)	Completed	USA	0
NCT04800822	Phase I	PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892	PF-07284892 in Participants With Advanced Solid Tumors	Active, not recruiting	USA	0
NCT03334617	Phase II	Danvatirsen + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab	Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)	Active, not recruiting	USA \| FRA \| ESP \| DEU \| CAN \| AUT	2
NCT04171622	Phase II	Lenvatinib + Pembrolizumab	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT05029882	Phase I	ABBV-400 + Bevacizumab ABBV-400 Bevacizumab + Trifluridine-tipiracil hydrochloride	Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab	Recruiting	USA \| FRA \| ESP \| AUS	6
NCT03865082	Phase II	IMO-2125 + Ipilimumab + Nivolumab	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)	Active, not recruiting	USA	0
NCT05388123	Phase II	Rituximab + Vemurafenib	Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia	Recruiting	USA	0
NCT02143050	Phase Ib/II	Dabrafenib + Metformin + Trametinib	Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients	Withdrawn	USA	0
NCT03693170	Phase II	Binimetinib + Cetuximab + Encorafenib	Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL \| AUT	1
NCT05223673	Phase III	Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)	Terminated	USA \| BEL	4
NCT01638676	Phase Ib/II	Metformin + Vemurafenib	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	Recruiting	USA	0
NCT05852223	Phase II	Pembrolizumab	Pembrolizumab in High-risk Thyroid Cancer (NePenThe)	Recruiting	ITA	0
NCT04619316	Phase II	Dabrafenib + Trametinib Trametinib	Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI)	Recruiting	DEU	0
NCT03475004	Phase II	Bevacizumab + Binimetinib + Pembrolizumab	Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer	Active, not recruiting	USA	0
NCT05777603	Phase I	Aztreonam + Pembrolizumab + Vancomycin	Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer	Recruiting	USA	0
NCT04044430	Phase Ib/II	Binimetinib + Encorafenib + Nivolumab	Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer	Terminated	USA	0
NCT05241873	Phase Ib/II	BLU-451	(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Active, not recruiting	USA \| CAN	3
NCT01897116	Phase I	Hydroxychloroquine + Vemurafenib	A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma	Completed	USA	0
NCT04787341	Phase II	Regorafenib Panitumumab	PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE)	Recruiting	ITA	0
NCT05957367	Phase Ib/II	DCC-3116 + Ripretinib Cetuximab + DCC-3116 + Encorafenib	A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies	Recruiting	USA	0
NCT05710406	Phase II	Cetuximab + Encorafenib	Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	Recruiting	USA	0
NCT05153408	Phase Ib/II	BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium	(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	Terminated	USA	0
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	7
NCT06364917	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab	DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC	Not yet recruiting	USA	0
NCT03181100	Phase II	Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel	Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer	Active, not recruiting	USA	0
NCT02034110	Phase II	Dabrafenib + Trametinib	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	5
NCT04017650	Phase Ib/II	Cetuximab + Encorafenib + Nivolumab	Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer	Recruiting	USA	0
NCT03708328	Phase I	RO7121661	A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors	Active, not recruiting	USA \| NZL \| FRA \| ESP	2
NCT03668431	Phase II	Dabrafenib + Spartalizumab + Trametinib	Dabrafenib + Trametinib + PDR001 In Colorectal Cancer	Recruiting	USA	0
NCT03189030	Phase I	pLADD	Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer	Terminated	USA	0
NCT05059470	Phase II	Pembrolizumab	IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC	Recruiting	USA	0
NCT04576117	Phase III	Selumetinib Selumetinib + Vinblastine	A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma	Recruiting	USA \| CAN	0
NCT03631706	Phase II	Bintrafusp alfa Pembrolizumab	M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL	10
NCT01750918	Phase II	Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib	BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| BEL	1
NCT05576896	Phase II	Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine	Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory	Recruiting	USA	0
NCT05026983	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases	Recruiting	USA	0
NCT05435846	Phase I	Capmatinib + Trametinib	Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation	Recruiting	USA	0
NCT03446157	Phase II	Cetuximab + Palbociclib	Palbociclib and Cetuximab in Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT02091141	Phase II	Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab	My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors	Completed	USA	0
NCT05768178	Phase II	Cobimetinib + Vemurafenib	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (DETERMINE)	Recruiting	GBR	0
NCT02974803	Phase II	Dabrafenib + Trametinib	Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Terminated	CAN	0
NCT01813214	Phase II	Vemurafenib	The Effects of Vemurafenib on Immunity in Patients With Melanoma	Terminated	USA	0
NCT02314481	Phase II	Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine	Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII)	Active, not recruiting	GBR	0
NCT02278133	Phase Ib/II	Cetuximab + Encorafenib + LGK974	Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations	Completed	USA \| NLD \| ITA \| FRA \| ESP \| CAN \| BEL \| AUS	2
NCT05180825	Phase II	Vinblastine Trametinib	Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC)	Recruiting	FRA	0
NCT01942993	Phase II	Vemurafenib	The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma	Terminated	USA	0
NCT03087071	Phase II	Panitumumab Panitumumab + Trametinib	Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer	Active, not recruiting	USA	0
NCT03592641	Phase II	Savolitinib	Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	Terminated	USA	0
NCT02230306	Phase II	Cobimetinib + Vemurafenib	Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases	Terminated	USA	0
NCT04059224	Phase II	Dabrafenib + Trametinib	TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)	Completed	BEL	0
NCT01436656	Phase I	Encorafenib	A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma	Completed	USA \| FRA \| ESP \| AUS	3
NCT04294160	Phase I	Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib	A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer	Active, not recruiting	USA \| NLD \| GBR \| ESP \| DEU \| CAN \| BEL \| AUS	2
NCT03301636	Phase II	Indoximod + Nivolumab Indoximod + Pembrolizumab	A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)	Terminated	USA	0
NCT03911869	Phase II	Binimetinib + Encorafenib	An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)	Terminated	USA \| ITA \| BEL \| AUS	1
NCT01844674	Phase I	Tizanidine + Vemurafenib	A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies	Completed	USA \| CAN	3
NCT02428712	Phase Ib/II	PLX8394	A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors	Active, not recruiting	USA	0
NCT03332589	Phase I	Dabrafenib + E6201 E6201	E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)	Terminated	USA	0
NCT03297606	Phase II	Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR)	Recruiting	CAN	0
NCT04417621	Phase II	LTT462 + LXH 254 Trametinib Ribociclib	Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| DEU \| BEL \| AUS	4
NCT01787500	Phase I	Cetuximab + Irinotecan + Vemurafenib	Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT04190628	Phase I	ABM-1310 ABM-1310 + Cobimetinib	Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors	Active, not recruiting	USA	0
NCT04741997	Phase I	Binimetinib + Encorafenib + Nivolumab Binimetinib + Encorafenib	Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma	Recruiting	USA	0
NCT01894672	Phase II	Encorafenib	BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation	Completed	USA	0
NCT02145910	Phase I	Vemurafenib	Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases	Withdrawn		0
NCT02068079	Phase I	Trientine + Vemurafenib	A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma	Withdrawn	USA	0
NCT05099003	Phase Ib/II	Selinexor	A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)	Suspended	USA \| NZL \| CAN \| AUS	0
NCT01767623	Phase I	Vemurafenib	A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients	Completed	USA \| GBR \| AUS	4
NCT02036086	Phase II	Cobimetinib + Vemurafenib	Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases	Active, not recruiting	CAN	0
NCT01524978	Phase II	Vemurafenib Cetuximab	A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers	Completed	USA \| GBR \| FRA \| ESP \| DEU	1
NCT04543188	Phase I	Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890	A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement	Terminated	USA \| CAN	1
NCT05299580	Phase II	Dabrafenib + Trametinib	Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)	Withdrawn	ITA	0
NCT02094872	Phase II	Doxorubicin	Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic	Completed	USA	0
NCT05221320	Phase II	Hydroxychloroquine + Ulixertinib	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Recruiting	USA	0
NCT06011772	Phase I	CIMAvax-EGF Bevacizumab + Cetuximab + CIMAvax-EGF + Leucovorin Bevacizumab + CIMAvax-EGF + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Oxaliplatin Cetuximab + CIMAvax-EGF + Fluorouracil + Irinotecan + Leucovorin	EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer	Recruiting	USA	0
NCT05358548	Phase II	Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab	ATATcH Alternating Treatment Plans for Advanced Cancer	Recruiting	USA	0
NCT03793179	Phase III	Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	Active, not recruiting	USA \| CAN	1
NCT04462471	Phase I	Copanlisib + Vemurafenib	Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Completed	USA	0
NCT04952753	Phase II	Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin	Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	8
NCT05593328	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation	Active, not recruiting	USA	0
NCT01543698	Phase Ib/II	Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib	A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors	Completed	USA \| ITA \| FRA \| ESP \| CAN \| BEL \| AUS	2
NCT01683188	Phase III	Aldesleukin + Vemurafenib	HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma	Terminated	USA	0
NCT03919071	Phase II	Dabrafenib + Trametinib	Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	Recruiting	USA	1
NCT04720768	Phase Ib/II	Binimetinib + Encorafenib + Palbociclib	Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)	Recruiting	AUS	0
NCT02039947	Phase II	Dabrafenib + Trametinib	Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain	Completed	USA \| ITA \| FRA \| ESP \| DEU \| CAN \| AUS	0
NCT02721459	Phase I	Cobimetinib + Vemurafenib + XL888	XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma	Active, not recruiting	USA	0
NCT05356897	Phase II	Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib	Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study	Not yet recruiting	USA	0
NCT01843738	Phase I	Vemurafenib	Radiation Use During Vemurafenib Treatment	Withdrawn	USA	0
NCT02145143	Phase 0	Vemurafenib	Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study	Active, not recruiting	USA	0
NCT01835184	Phase I	Cabozantinib + Vemurafenib	Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery	Terminated	USA	0
NCT01946789	Phase I	Nogapendekin alfa inbakicept	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT05722886	Phase II	Cobimetinib + Vemurafenib Alectinib Pertuzumab + Trastuzumab Entrectinib Atezolizumab	DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)	Recruiting	GBR	0
NCT05215340	Phase III	Pembrolizumab Datopotamab deruxtecan + Pembrolizumab	Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	17
NCT04221438	Phase II	Binimetinib + Encorafenib	Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement	Active, not recruiting	USA	0
NCT01820364	Phase II	Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib	LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma	Terminated	USA \| ESP \| DEU \| CAN \| AUS	1
NCT01902173	Phase Ib/II	Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib	Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	Active, not recruiting	USA	0
NCT04302025	Phase II	Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib	A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer	Recruiting	USA	0
NCT02961283	Phase I	ASN003	Study of ASN003 in Subjects With Advanced Solid Tumors	Terminated	USA	0
NCT05050006	Phase II	ITIL-168	ITIL-168 in Advanced Melanoma (DELTA-1)	Terminated	USA \| GBR \| CAN	0
NCT01981187	Phase II	Encorafenib	LGX818 for Patients With BRAFV600 Mutated Tumors	Terminated	USA	0
NCT02159066	Phase II	Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib	LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma	Completed	USA \| NLD \| ITA \| GBR \| ESP \| DEU \| CAN \| AUS	1
NCT04511013	Phase II	Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab	A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases	Recruiting	USA	0
NCT03442569	Phase II	Ipilimumab + Nivolumab + Panitumumab	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC	Active, not recruiting	USA	0
NCT01907802	Phase I	Dabrafenib	Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction	Terminated	USA \| CAN	0
NCT01677741	Phase I	Dabrafenib	A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	2
NCT03992456	Phase II	Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride	Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	Active, not recruiting	USA	0
NCT03754179	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)	Unknown status	BEL	0
NCT02723006	Phase I	Nivolumab + Tovorafenib MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab	Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma	Terminated	USA	0
NCT05388877	Phase I	Dabrafenib + E6201	E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma	Recruiting	USA	0
NCT04145297	Phase I	Hydroxychloroquine + Ulixertinib	Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH)	Completed	USA	0
NCT03178851	Phase I	Atezolizumab Atezolizumab + Cobimetinib	Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma	Completed	USA \| ESP \| AUS	4
NCT02082665	Phase I	Dabrafenib + Midazolam + Rosuvastatin	Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam	Completed	USA \| ESP	0
NCT02456701	Phase I	CDX-3379 + Vemurafenib	Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379	Completed	USA	0
NCT04375527	Phase II	Binimetinib + Nivolumab	Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma	Recruiting	USA	0
NCT01777776	Phase Ib/II	Encorafenib Encorafenib + Ribociclib	Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.	Terminated	USA \| NLD \| CAN \| AUS	0
NCT05668585	Phase Ib/II	CFT1946 + Trametinib CFT1946	A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors	Recruiting	USA \| FRA \| ESP	0
NCT03543969	Phase I	Cobimetinib + Vemurafenib	Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma	Recruiting	USA	0
NCT01656642	Phase I	Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib	A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma	Completed	USA	0
NCT02967692	Phase III	Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib	A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	18
NCT01826448	Phase I	Pexidartinib + Vemurafenib	A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma	Terminated	USA \| FRA \| DEU	0
NCT01954043	Phase I	Dabrafenib + Rabeprazole + Rifampin	A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors	Completed	USA \| GBR \| AUS	0
NCT01701037	Phase II	Dabrafenib + Trametinib Dabrafenib	Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery	Terminated	USA	0
NCT05275374	Phase Ib/II	BI 882370 + Trametinib BI 882370	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)	Not yet recruiting		0
NCT03581292	Phase II	Temozolomide + Veliparib Veliparib	Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	Active, not recruiting	USA \| NZL \| CAN \| AUS	1
NCT03005639	Phase II	Cobimetinib + Vemurafenib	ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma	Withdrawn	USA	0
NCT01619774	Phase II	Dabrafenib + Trametinib	An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor	Completed	USA	0
NCT03220035	Phase II	Vemurafenib	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT03149029	Phase II	Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib	Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma	Active, not recruiting	USA	0
NCT01603212	Phase Ib/II	Aldesleukin + Alpha 2 Interferon + Vemurafenib	Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor	Completed	USA	0
NCT03155620	Phase II	Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Recruiting	USA \| CAN \| AUS	1
NCT02906059	Phase I	Adavosertib + Irinotecan	Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer	Completed	USA	0
NCT01974258	Phase I	Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib	Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients	Withdrawn	USA	0
NCT04903119	Phase I	Dabrafenib + Nilotinib + Trametinib	Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma	Recruiting	USA	0
NCT01738451	Phase I	Dabrafenib	A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors	Completed	USA \| GBR \| AUS	0
NCT03377361	Phase Ib/II	Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9)	Active, not recruiting	USA \| ITA \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT01519323	Phase I	Vemurafenib	BRIM-P	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| AUS	3
NCT02263898	Phase II	Binimetinib + Encorafenib	Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations	Withdrawn	USA	0
NCT01739764	Phase III	Vemurafenib	An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol	Completed	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL	15
NCT03273153	Phase III	Pembrolizumab Atezolizumab + Cobimetinib	A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma	Terminated	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS	6
NCT01562899	Phase II	Binimetinib + Ganitumab	A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| CAN \| BEL \| AUS	0
NCT02908672	Phase III	Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib	A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma	Active, not recruiting	USA \| NZL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT \| AUS	8
NCT04587128	Phase II	Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab	Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC	Recruiting	USA	0
NCT04488003	Phase II	Ulixertinib	Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations	Terminated	USA	0
NCT06024174	Phase Ib/II	Adagrasib + BBP-398 + Cetuximab Adagrasib + BBP-398	A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors	Active, not recruiting	USA \| ITA \| FRA \| ESP \| BEL \| AUS	2
NCT04324112	Phase II	Binimetinib + Encorafenib	Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL	Recruiting	USA	0
NCT06106308	Phase II	Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Recruiting	USA	0
NCT01514864	Phase II	Dasatinib	Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation	Terminated	USA \| GBR \| DEU \| CAN	3
NCT03634982	Phase I	RMC-4630	Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors	Unknown status	USA	0
NCT03989115	Phase Ib/II	Cobimetinib + RMC-4630 Osimertinib + RMC-4630	Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC	Completed	USA	1
NCT02138292	Phase I	Digoxin + Trametinib	A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma	Completed	USA	0
NCT04616183	Phase Ib/II	Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996	LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer	Active, not recruiting	USA	0
NCT03384940	Phase II	Trastuzumab deruxtecan	DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)	Completed	USA \| ITA \| GBR \| ESP	1
NCT02318901	Phase Ib/II	Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab	Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer	Terminated	USA	0
NCT04129515	Phase Ib/II	Pembrolizumab	NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis	Not yet recruiting	USA	0
NCT03457896	Phase II	Cetuximab + Neratinib Neratinib + Trastuzumab	Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status	Unknown status	USA	0
NCT04434560	Phase II	Ipilimumab + Nivolumab	Neoadjuvant Immunotherapy in Brain Metastases	Terminated	USA	0
NCT02785068	Phase I	Fluorouracil + Irinotecan + Leucovorin + MM-151	Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer	Withdrawn		0
NCT04322383	Phase II	Binimetinib	Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant	Recruiting	USA	0
NCT01941927	Phase II	Trametinib + Uprosertib	Trametinib With GSK2141795 in BRAF Wild-type Melanoma	Completed	USA	0
NCT02508077	Phase II	Fluorouracil + Irinotecan + Leucovorin Panitumumab	FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer	Terminated	USA	0
NCT01960023	Phase Ib/II	Cetuximab + Neratinib	Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer	Withdrawn	USA	0
NCT04744831	Phase II	Trastuzumab deruxtecan	Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02)	Active, not recruiting	USA \| ITA \| GBR \| FRA \| ESP \| BEL \| AUS	3
NCT01802320	Phase II	MK2206	Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery	Completed	USA	0
NCT01138085	Phase I	Trametinib + Uprosertib	Safety, Pharmacokinetics (PK) of AKT and MEK Combination	Completed	USA	0
NCT03069950	Phase II	Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver	Withdrawn	USA	0
NCT03580382	Phase Ib/II	CDX-3379 + Trametinib	Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma	Terminated	USA	0
NCT05619172	Phase II	Cetuximab + SOT101	A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer	Active, not recruiting	FRA \| ESP \| BEL	0
NCT05487235	Phase I	Atezolizumab + GDC-1971 Atezolizumab + GDC-1971 + Omeprazole	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Recruiting	USA \| NZL \| ESP \| CAN \| AUS	4
NCT01449058	Phase Ib/II	Alpelisib + Binimetinib	A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors	Completed	USA \| ITA \| GBR \| FRA \| ESP \| AUS	1
NCT05502237	Phase III	AB154 + Cisplatin + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel Cisplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Nab-paclitaxel AB154 + Carboplatin + Pemetrexed Disodium + Zimberelimab Carboplatin + Pembrolizumab + Pemetrexed Disodium AB154 + Carboplatin + Paclitaxel + Zimberelimab AB154 + Carboplatin + Nab-paclitaxel + Zimberelimab AB154 + Carboplatin + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab AB154 + Cisplatin + Pemetrexed Disodium + Zimberelimab	Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUT	13
NCT04511845	Phase I	SPYK04	A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).	Recruiting	USA	1
NCT03555149	Phase Ib/II	Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan	A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)	Terminated	USA \| FRA \| AUS	2
NCT04495621	Phase Ib/II	Cetuximab + MEN1611	MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01)	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU	1
NCT03391232	Phase I	PolyPEPI1018	Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)	Completed	USA \| ITA	0
NCT06328738	Phase I	ELVN-002 + Eribulin + Trastuzumab Capecitabine + ELVN-002 + Trastuzumab ELVN-002 + Paclitaxel + Trastuzumab Capecitabine + ELVN-002 + Oxaliplatin + Trastuzumab ELVN-002 + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab ELVN-002 + Trastuzumab	ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer	Recruiting	USA	0
NCT01231594	Phase I	Dabrafenib Trametinib	A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors	Completed	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	1
NCT04270591	Phase Ib/II	SCC244	Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer	Recruiting	USA	2
NCT05831995	Phase I	ABM-168	Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.	Recruiting	USA	0
NCT05259319	Phase I	Atezolizumab + Tiragolumab	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT)	Recruiting	FRA	0
NCT05564377	Phase II	Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Recruiting	USA	1
NCT04566393	Expanded access	Ulixertinib	Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies	Available	USA	0
NCT05312398	Phase II	Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin	CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen	Active, not recruiting	ITA	0
NCT05836324	Phase I	INCA33890	A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors	Recruiting	USA \| ITA \| GBR \| FRA \| ESP	2
NCT06005974	Phase II	TAK-733	A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation	Recruiting	USA	0
NCT05201352	Phase Ib/II	Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001	Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN)	Recruiting	FRA	0
NCT05117242	Phase II	GEN1046 + Pembrolizumab GEN1046	Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer	Recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	2
NCT03213691	Phase II	Selumetinib	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT03784378	Phase I	RXDX-105	Continued Access to RXDX-105	Completed	USA	0
NCT04515394	Phase II	Cetuximab + Tepotinib	Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| BEL	2
NCT03874026	Phase II	Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA)	Recruiting	ITA	0
NCT05609370	Phase Ib/II	Bevacizumab + Capecitabine Bevacizumab + Fluorouracil + LBL-007 + Tislelizumab Bevacizumab + Fluorouracil + LBL-007 Bevacizumab + Fluorouracil Bevacizumab + Capecitabine + LBL-007 + Tislelizumab Bevacizumab + Capecitabine + LBL-007	A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer	Recruiting	USA \| AUS	2
NCT02857270	Phase I	LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996	A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Completed	USA \| FRA \| AUS	1
NCT00770263	Phase I	Erlotinib + Temsirolimus	Erlotinib and Temsirolimus for Solid Tumors	Completed	USA	0
NCT04409639	Phase II	Cobimetinib	Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO)	Recruiting	USA	0
NCT03698994	Phase II	Ulixertinib	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Active, not recruiting	USA	1
NCT03664024	Phase II	Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium	Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)	Completed	USA \| ESP \| CAN	2
NCT02407509	Phase I	RO5126766 Everolimus + RO5126766	Phase I Trial of VS-6766 Alone and in Combination With Everolimus (RAF/MEK)	Recruiting	GBR	0
NCT03091257	Phase I	Dabrafenib + Trametinib Dabrafenib Trametinib	A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma	Recruiting	USA	0
NCT06326411	Phase I	NST-628	A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628)	Recruiting	AUS	0
NCT03162627	Phase I	Olaparib + Selumetinib	Selumetinib and Olaparib in Solid Tumors	Active, not recruiting	USA	0
NCT02860780	Phase I	Prexasertib + Ralimetinib	A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer	Completed	USA \| DEU	0
NCT04925986	Phase II	Pembrolizumab + Sitravatinib	Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC	Terminated	USA	0
NCT04620330	Phase II	Defactinib + RO5126766 RO5126766	A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (RAMP202)	Completed	USA \| ITA \| FRA \| ESP \| DEU	0
NCT05759728	Phase Ib/II	CNA3103	A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer	Recruiting	AUS	0
NCT02974725	Phase I	LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254	A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma	Active, not recruiting	USA \| ITA \| FRA \| ESP \| DEU \| BEL \| AUS	4
NCT03696212	Phase Ib/II	Grapiprant + Pembrolizumab	Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma	Terminated	USA	0
NCT01744652	Phase I	Crizotinib + Dasatinib	Dasatinib and Crizotinib in Advanced Cancer	Completed	USA	0
NCT03972046	Phase II	Dabrafenib + Talimogene laherparepvec + Trametinib	Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma	Withdrawn	USA	0
NCT04609566	Phase II	Brentuximab vedotin + Pembrolizumab	Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors	Recruiting	USA \| CAN	0
NCT03051035	Phase I	KO-947	First-in-Human Study of KO-947 in Non-Hematological Malignancies	Terminated	USA \| ESP	0
NCT01781429	Phase Ib/II	Ulixertinib	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies	Completed	USA	0
NCT03875820	Phase I	Defactinib + RO5126766	Phase I Trial of Defactinib and VS-6766. (FRAME)	Active, not recruiting	GBR	0
NCT06067776	Phase I	Cetuximab + Osimertinib + Tucatinib	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	Not yet recruiting	USA	0
NCT06299839	Phase I	PAS-004	PAS-004 in Patients With Advanced Solid Tumors	Recruiting	USA	0
NCT04776655	Phase III	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin	Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb)	Recruiting	ITA	0
NCT05629702	Phase II	Nabiximols + Temozolomide Temozolomide	ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids (ARISTOCRAT)	Recruiting	GBR	0
NCT05379595	Phase Ib/II	Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin	A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1)	Recruiting	USA \| ITA \| ESP \| DEU \| CAN \| BEL	5
NCT01719380	Phase Ib/II	Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib	Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer	Completed	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	3
NCT03559049	Phase Ib/II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib	Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer	Active, not recruiting	USA	0
NCT01531361	Phase I	Sorafenib + Vemurafenib Crizotinib + Vemurafenib	Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations	Completed	USA	0
NCT01885195	Phase II	Binimetinib	MEK162 for Patients With RAS/RAF/MEK Activated Tumors	Completed	USA	0
NCT01037790	Phase II	Palbociclib	PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER	Completed	USA	0
NCT01841463	Phase Ib/II	Vemurafenib + Voruciclib	Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation	Suspended	USA	0
NCT04524689	Phase II	Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701	Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) (CARMEN-LC05)	Active, not recruiting	USA \| FRA \| ESP	5
NCT02648490	Phase I	Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07	An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	Completed	USA	1
NCT03867799	Phase II	Nivolumab + Relatlimab	iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer	Active, not recruiting	GBR	0
NCT06208748	Phase II	PLX9486 + Sunitinib	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Not yet recruiting	USA	0
NCT04072198	Phase II	Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin	Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR)	Unknown status	ITA	0
NCT03037385	Phase Ib/II	Pralsetinib	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL	5
NCT02610361	Phase I	Lifirafenib	Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors	Completed	NZL \| AUS	0
NCT04189055	Phase II	Cetuximab + Irinotecan Cetuximab	Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)	Recruiting	FRA	0
NCT04457284	Phase II	Cisplatin + Nivolumab + Temozolomide	Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer	Active, not recruiting	USA	0
NCT04105270	Phase II	Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial	Recruiting	USA	0
NCT01723202	Phase II	Dabrafenib + Trametinib Dabrafenib	Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer	Active, not recruiting	USA	0
NCT01351103	Phase I	LGK974 LGK974 + Spartalizumab	A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Active, not recruiting	USA \| NLD \| ITA \| FRA \| ESP \| DEU \| CAN	0
NCT01306045	Phase II	Erlotinib Lapatinib MK2206 Sunitinib Selumetinib	Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Active, not recruiting	USA	0
NCT03396497	Phase I	LYC-55716 + Pembrolizumab	Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer	Unknown status	USA	0
NCT03475953	Phase Ib/II	Avelumab + Regorafenib	A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE)	Recruiting	FRA	0
NCT06116786	Phase I	Cetrelimab + JNJ-86974680	A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Recruiting	USA \| ESP \| DEU	1
NCT04370704	Phase Ib/II	INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390	Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies	Active, not recruiting	USA \| AUS	0
NCT05291156	Phase II	Cetuximab Avelumab + Cetuximab	CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy	Recruiting	ITA	0
NCT04892017	Phase Ib/II	DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib	A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors	Recruiting	USA	0
NCT04921358	Phase III	Docetaxel Sitravatinib + Tislelizumab	Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Terminated	AUS	1
NCT04591431	Phase II	Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib	The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME)	Active, not recruiting	ITA	0
NCT03415126	Phase I	ERAS-007	A Study of ASN007 in Patients With Advanced Solid Tumors	Completed	USA	0
NCT04425239	Phase II	Fluorouracil + Irinotecan + Leucovorin + Panitumumab	Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE)	Completed	ITA	0
NCT06287463	Phase Ib/II	DCC-3084	Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway	Not yet recruiting	USA	0
NCT05886920	Phase I	D3S-002	Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations	Recruiting	USA \| AUS	1
NCT02747537	Phase II	Irinotecan + Sorafenib	Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan	Withdrawn		0
NCT03218826	Phase I	AZD8186 + Docetaxel	PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	Active, not recruiting	USA	0
NCT02050321	Phase II	Acitretin + Vemurafenib	A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma	Terminated	USA	0

Gene Detail

Contact

Filtering

Sorting